Aardvark Therapeutics (AARD) Operating Income (2024 - 2026)
Aardvark Therapeutics (AARD) posted Operating Income of -$22.5 million for Q1 2026, down 20.1% sequentially from -$18.7 million in Q4 2025, and down 114.56% YoY from $154.3 million in Q1 2025.
Aardvark Therapeutics (AARD) Operating Income (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Operating Income for 3 years, with the latest figure at -$22.5 million in Q1 2026.
- Quarterly Operating Income fell 114.56% year-over-year to -$22.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$74.7 million (down 140.38% YoY) and the FY2025 annual result came in at -$62.7 million, down 175.29% from the prior year.
- Operating Income retreated to -$22.5 million in Q1 2026 per AARD's latest filing, from -$18.7 million in the prior quarter.
- Over five years, Operating Income peaked at -$2.2 million in Q1 2024 and troughed at -$22.5 million in Q1 2026.
- A 3-year average of -$12.0 million and a median of -$10.5 million in 2025 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 97.93% in 2025, down 382.27% in 2025.
- Over 3 years, Operating Income stood at -$9.4 million in 2024, then plunged by 97.93% to -$18.7 million in 2025, then fell by 20.1% to -$22.5 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$22.5 million, -$18.7 million, and -$17.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | Aardvark Therapeutics | 148.77 Mn | 74.85 Mn | - | -15.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.08 Mn |
| Mar 31, 2026 | -22.46 Mn |
| Dec 31, 2025 | -18.70 Mn |
| Sep 30, 2025 | -17.70 Mn |
| Jun 30, 2025 | -15.85 Mn |
| Mar 31, 2025 | -10.47 Mn |
| Dec 31, 2024 | -9.45 Mn |
| Sep 30, 2024 | -5.09 Mn |
| Jun 30, 2024 | -6.07 Mn |
| Mar 31, 2024 | -2.17 Mn |